Category Industry Updates

Natera to Support Clinical Trial Evaluating ctDNA Dynamics with Latitude™ in Advanced Skin Cancer

Natera Collaborates With Kupando Therapeutics to Monitor Molecular Response in Phase 1 Trial of Novel Immunotherapy KUP-101 Natera, Inc., a global leader in cell-free DNA analysis and precision medicine, has announced a new collaboration with Kupando Therapeutics to support a…

Read MoreNatera to Support Clinical Trial Evaluating ctDNA Dynamics with Latitude™ in Advanced Skin Cancer

Integrated DNA Technologies Scientists Establish New Benchmark for CRISPR Off-Target Detection

Integrated DNA Technologies Study Establishes New Benchmark for CRISPR Off-Target Detection and Analysis Integrated DNA Technologies (IDT), a Danaher company and a global provider of genomics solutions, has announced the publication of a new peer-reviewed study in Nature Communications that…

Read MoreIntegrated DNA Technologies Scientists Establish New Benchmark for CRISPR Off-Target Detection

Bruker Makes Majority Investment in MIMETAS to Advance Human-Relevant Drug Discovery

Bruker Expands Drug Discovery Capabilities with Majority Investment in MIMETAS and Organ-on-a-Chip Technology Bruker Corporation has announced a majority investment in MIMETAS B.V., a biotechnology company specializing in organ-on-a-chip platforms and advanced human tissue and disease models for pharmaceutical research…

Read MoreBruker Makes Majority Investment in MIMETAS to Advance Human-Relevant Drug Discovery

Expedition Therapeutics Secures Oversubscribed $115 Million Series B to Advance Next-Generation COPD Therapy

Expedition Therapeutics Raises Oversubscribed $115 Million Series B Financing and Advances EXPD-101 into Phase 2 Clinical Trial for COPD Expedition Therapeutics, a clinical-stage biotechnology company focused on developing innovative oral small-molecule therapies for inflammatory and respiratory diseases, has announced two…

Read MoreExpedition Therapeutics Secures Oversubscribed $115 Million Series B to Advance Next-Generation COPD Therapy

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher to Accelerate Drug Development

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher to Accelerate Plozasiran Approval for Severe Hypertriglyceridemia Arrowhead Pharmaceuticals, Inc. has announced that it has entered into an agreement with an undisclosed third party to acquire a U.S. Food and Drug Administration (FDA)…

Read MoreArrowhead Pharmaceuticals Acquires FDA Priority Review Voucher to Accelerate Drug Development

Family Heart Foundation CEO Katherine Wilemon Receives ASPC Honorary Fellow Award

Family Heart Foundation Founder Katherine Wilemon Receives ASPC 2026 Honorary Fellow Award for Advancing Cardiovascular Disease Prevention The Family Heart Foundation, a leading nonprofit organization dedicated to research, education, advocacy, and patient support for inherited cardiovascular diseases, has announced that…

Read MoreFamily Heart Foundation CEO Katherine Wilemon Receives ASPC Honorary Fellow Award

Pfizer-BioNTech XFG-Adapted COVID-19 Vaccine Receives EU Authorization

Pfizer and BioNTech Receive European Commission Approval for 2026–2027 XFG-Adapted COVID-19 Vaccine Across Europe Pfizer Inc. and BioNTech SE have announced that the European Commission (EC) has granted marketing authorization for their updated 2026–2027 COVID-19 vaccine, specifically designed to target…

Read MorePfizer-BioNTech XFG-Adapted COVID-19 Vaccine Receives EU Authorization

Mainstay Medical Announces Highmark Coverage Milestone for ReActiv8®

Mainstay Medical Achieves Coverage Milestone with Highmark Mainstay Medical Holdings plc has announced a significant reimbursement milestone for its ReActiv8 Restorative Neurostimulation™ therapy, following a favorable coverage decision from Highmark Inc. The new medical policy, which became effective on July…

Read MoreMainstay Medical Announces Highmark Coverage Milestone for ReActiv8®